The FDA issued draft guidance outlining how sponsors should pursue approvals and postapproval management for individualized human genome editing products, aimed at rare genetic diseases. The proposal—FDA-2026-D-11783—introduces a framework for Biologics License Applications (BLAs) that can cover patient-specific edits without requiring a separate trial for every variant class.